Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.
Michael K. Gould, MD, MS
Advertisement
Articles by Michael K. Gould, MD, MS
Advertisement
Latest Updated Articles
Dr. Gould on the Implications of the NELSON Trial in Lung CancerPublished: March 11th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5